Maravai LifeSciences Holdings Management
Management criteria checks 4/4
Maravai LifeSciences Holdings' CEO is Trey Martin, appointed in Jul 2023, has a tenure of 1.17 years. total yearly compensation is $2.30M, comprised of 32.6% salary and 67.4% bonuses, including company stock and options. directly owns 0.15% of the company’s shares, worth $3.17M. The average tenure of the management team and the board of directors is 2.3 years and 3.8 years respectively.
Key information
Trey Martin
Chief executive officer
US$2.3m
Total compensation
| CEO salary percentage | 32.6% |
| CEO tenure | 1.2yrs |
| CEO ownership | 0.2% |
| Management average tenure | 2.3yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) 29% Jump Shows Its Popularity With Investors
Jul 18
Does Maravai LifeSciences Holdings (NASDAQ:MRVI) Have A Healthy Balance Sheet?
Jul 15Maravai: Embedded Expectations Remain Too High Considering Economic Calculus
Jul 12RGA Investment Advisors - Maravai: Two Elite Assets With Other-Worldly Margins Wrapped In One
Jun 12Revenues Tell The Story For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) As Its Stock Soars 25%
May 14An Intrinsic Calculation For Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Suggests It's 23% Undervalued
Apr 07Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Feb 28Revenues Working Against Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price
Dec 19Need To Know: Analysts Just Made A Substantial Cut To Their Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Estimates
Aug 14Are Investors Undervaluing Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) By 27%?
Feb 28Is Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Expensive For A Reason? A Look At Its Intrinsic Value
Nov 01Maravai Lifesciences temporarily reinstates Carl Hull as CEO
Oct 19Maravai LifeSciences appoints former Danaher executive as CEO
Oct 03Maravai LifeSciences Holdings GAAP EPS of $0.53 beats by $0.15, revenue of $242.73M beats by $9.51M
Aug 04Estimating The Intrinsic Value Of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)
Jun 27Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Intrinsic Value Is Potentially 25% Below Its Share Price
Mar 29Maravai Faces Skeptical Investors As Pandemic Enters New Period
Jan 27Maravai LifeSciences Holdings, Inc.'s (NASDAQ:MRVI) Share Price Could Signal Some Risk
Dec 02CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$132m |
| Mar 31 2024 | n/a | n/a | -US$131m |
| Dec 31 2023 | US$2m | US$750k | -US$119m |
| Sep 30 2023 | n/a | n/a | US$25m |
| Jun 30 2023 | n/a | n/a | US$75m |
| Mar 31 2023 | n/a | n/a | US$153m |
| Dec 31 2022 | US$15m | US$660k | US$220m |
Compensation vs Market: Trey's total compensation ($USD2.30M) is below average for companies of similar size in the US market ($USD5.58M).
Compensation vs Earnings: Trey's compensation has been consistent with company performance over the past year.
CEO
Trey Martin (49 yo)
1.2yrs
Tenure
US$2,301,864
Compensation
Mr. William E. Martin, III, also known as Trey, is Director of Maravai LifeSciences Holdings, Inc. from July 31, 2024. He was President of Biologics Safety Testing of Maravai LifeSciences Holdings, Inc. si...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 3.8yrs | US$5.22m | 0.21% $ 4.4m | |
| CEO & Director | 1.2yrs | US$2.30m | 0.15% $ 3.2m | |
| Executive VP & CFO | 7.3yrs | US$2.79m | 0.021% $ 440.7k | |
| Executive VP & Chief Administrative Officer | 2.3yrs | US$2.83m | 0.040% $ 834.2k | |
| Executive VP & GM of Cygnus Technologies | 6.9yrs | US$2.26m | 0.018% $ 387.8k | |
| President of Nucleic Acid Production | 1.5yrs | US$2.99m | 0.023% $ 476.1k | |
| Senior Director of Investor Relations | no data | no data | no data | |
| Executive VP | 3.8yrs | US$701.40k | 0.018% $ 381.0k | |
| Executive VP & Chief Commercial Officer | 1.6yrs | no data | 0.014% $ 293.1k | |
| Chief Innovation Officer | 1.6yrs | no data | no data |
2.3yrs
Average Tenure
55yo
Average Age
Experienced Management: MRVI's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder & Executive Chairman | 3.8yrs | US$5.22m | 0.21% $ 4.4m | |
| CEO & Director | less than a year | US$2.30m | 0.15% $ 3.2m | |
| Independent Director | 1.2yrs | US$435.03k | no data | |
| Non-Independent Director | 3.8yrs | US$370.48k | 0.0030% $ 63.7k | |
| Non-Independent Director | 3.8yrs | US$367.98k | 0.0030% $ 63.7k | |
| Independent Director | 3.8yrs | US$360.48k | 0.022% $ 463.7k | |
| Independent Director | 3.8yrs | US$395.48k | 0.026% $ 538.1k | |
| Non-Independent Director | 3.8yrs | US$360.48k | 0.0030% $ 63.7k | |
| Non-Independent Director | 3.8yrs | US$360.48k | 0.0030% $ 63.7k | |
| Independent Director | 3.8yrs | US$367.98k | 0.015% $ 310.2k | |
| Independent Director | 3.8yrs | US$387.98k | 0.047% $ 985.0k |
3.8yrs
Average Tenure
59yo
Average Age
Experienced Board: MRVI's board of directors are considered experienced (3.8 years average tenure).